Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

Original reporting
Published Nov 17, 2026, 3:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Omeros (OMER) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$OMERBullishMed
01

Why it matters

The transcript emphasizes accelerating account adoption, outpatient utilization via 340B, and a Medicare NTAP add-on effective Oct. 1, while also explaining GAAP losses driven by noncash marks on embedded derivatives in its 2029 convertible notes.

02

Market read

Traders get actionable commercialization and reimbursement datapoints (account growth, outpatient 340B participation, NTAP effective date) plus capital-structure actions (convertible note repurchases) that can shift near-term sentiment.

03

What to watch

340B reimbursement rule changes begin Jan. 1, 2027, so traders should monitor whether YARTEMLEA’s pass-through status and outpatient economics remain favorable beyond June 2029.

Relevance 7/10Novelty 6/10Timing: during/after the Q3 earnings call transcript release

Background

Omeros’ Q3 2026 earnings call focuses on YARTEMLEA commercialization progress for TA-TMA, including field education expansion and reimbursement positioning.

Company-level read

Ticker impact

$OMERBullishMedium confidence
Context

Omeros reports Q3 YARTEMLEA sales growth, expanding outpatient 340B use, and highlights Medicare NTAP reimbursement effective Oct. 1.

Expected impact

Likely upward bias as traders focus on accelerating adoption, reimbursement tailwinds (NTAP), and reduced convertible-note overhang.

Evidence & confidence

The transcript provides multiple decision-relevant datapoints (sales growth, account growth, NTAP effective date, and share/convertible repurchases) but is not a fresh earnings print with new guidance beyond the call’s disclosed quarter results.

Market effects

Reimbursement mechanics (NTAP and 340B rule changes) can influence sentiment toward other transplant and specialty biotech commercialization models.

Primarily US-focused reimbursement and transplant-center adoption dynamics.

Limited direct global read-through; reimbursement policy is US-specific.

Counterpoint

GAAP results remain deeply loss-making due to noncash derivative remeasurement, so equity upside may be capped until operating profitability and cash burn trajectory improve.

Key entities

  • Omeros

    US-listed biotech (OMER) commercializing YARTEMLEA and managing convertible-note dilution/interest exposure.

  • YARTEMLEA

    TA-TMA therapy whose sales growth and reimbursement advantages are central to the call.

  • 340B reimbursement

    CMS rule changes effective Jan. 1, 2027, with transitional pass-through status affecting economics.

  • NTAP

    Medicare technology add-on payment providing up to $287,000 additional reimbursement per eligible inpatient case.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q